Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CORT

CORT - Corcept Therapeutics Inc Stock Price, Fair Value and News

$45.82-0.40 (-0.87%)
Market Closed

59/100

CORT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

59/100

CORT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$45.83

Target 3M

$44.42

Target 6M

$44.9

CORT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CORT Price Action

Last 7 days

26.2%

Last 30 days

-42.6%

Last 90 days

-36.6%

Trailing 12 Months

-24.5%

CORT RSI Chart

CORT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CORT Valuation

Market Cap

4.8B

Price/Earnings (Trailing)

45.42

Price/Sales (Trailing)

6.5

EV/EBITDA

52.36

Price/Free Cashflow

29.55

CORT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$45.83

Target 3M

$44.42

Target 6M

$44.9

CORT Fundamentals

CORT Revenue

Revenue (TTM)

741.2M

Rev. Growth (Yr)

13.75%

Rev. Growth (Qtr)

6.79%

CORT Earnings

Earnings (TTM)

106.1M

Earnings Growth (Yr)

-58.34%

Earnings Growth (Qtr)

-44.04%

CORT Profitability

Operating Margin

99.82%

EBT Margin

11.94%

Return on Equity

16.79%

Return on Assets

12.88%

Free Cashflow Yield

3.38%

CORT Investor Care

Shares Dilution (1Y)

0.39%

Diluted EPS (TTM)

0.87

CORT Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025685.4M716.1M741.2M0
2024523.5M569.6M628.6M675.0M
2023413.8M428.2M450.0M482.4M
2022380.2M392.0M397.6M401.9M
2021340.1M343.1M352.9M366.0M
2020334.9M351.2M356.0M353.9M
2019258.4M268.4M285.4M306.5M
2018189.3M216.0M237.7M251.2M
201792.9M108.7M129.7M159.2M
201656.2M64.0M72.5M81.3M
201532.2M38.4M44.3M50.3M
201413.0M17.0M21.7M26.6M
20135.0M6.0M7.6M10.4M
20122.4M2.7M3.0M3.3M
2011001.8M2.1M
20100566.0K1.0M1.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Corcept Therapeutics Inc

CORT
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
 CEO
 WEBSITEcorcept.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES299

Corcept Therapeutics Inc Frequently Asked Questions

CORT is the stock ticker symbol of Corcept Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Corcept Therapeutics Inc is 4.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CORT's fair value in chart for subscribers.

The fair value guage provides a quick view whether CORT is over valued or under valued. Whether Corcept Therapeutics Inc is cheap or expensive depends on the assumptions which impact Corcept Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CORT.

As of Wed Jan 28 2026, CORT's PE ratio (Price to Earnings) is 45.42 and Price to Sales (PS) ratio is 6.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CORT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Corcept Therapeutics Inc has provided 0.288 (multiply by 100 for percentage) rate of return.